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Every year, osteoporosis causes millions of fractures world-wide, with the lifetime risk of suffering a wrist, hip, or
vertebral fracture estimated to be about 30% in developed
countries.(1) Osteoporosis has been operationally deﬁned for
diagnostic and treatment purposes on the basis of the bone
mineral density (BMD) assessment performed at the skeletal
sites where fracture is most common. Nevertheless, BMD
measurement alone is not optimal for the detection of
individuals at high risk of fracture. Despite high speciﬁcity (ie,
risk of fracture is high when BMD is low), BMDmeasurement also
holds low sensitivity (ie, risk is still substantial when BMD levels
do not indicate the presence of osteoporosis). This has to do
with the multifactorial etiology of osteoporosis and its
associated fractures, involving signiﬁcant environmental inﬂu-
ences together with a very large set of genetic factors acting
across numerous biological processes. Multiple underlying
factors, apart from bone strength, inﬂuence the risk of fracture,
including age, sex, menopausal status, diet, physical activity,
smoking, falls risk, coexisting diseases, and medications. Among
the established risk factors, the predictive ability of family history
of fracture has led researchers to start looking for the molecular
genetic determinants of fracture. Such enterprises usually start
by determining how much of the phenotypic variance is
explained by genetic factors, ie, determining the “heritability” of
the traits of interest. Theoretically, identifying the factors that
together constitute the genetic contribution to fracture risk will
expand the understanding of the underlying biologic mecha-
nisms, lead to development of novel interventions (treatments),
and will enable the application of molecular deﬁnitions to
reclassify disease and improve risk prediction. Until 2005, the
identiﬁcation of genetic factors for complex diseases such as
osteoporosis was plagued with underpowered and irreproduc-
ible studies of suspected (well-known) candidate genes in
human studies (eg, cases/controls, families, sib pairs, and
populations). It was, however, realized that collaboration could
overcome several of these hurdles, and this concept proved
successful when hypothesis-free interrogations of the complete
genome were made possible by novel massively parallel
genotyping techniques that analyzed millions of DNA polymor-
phisms simultaneously. As in other human complex diseases,
the ﬁeld of genetics of osteoporosis has been revolutionized by
the advent of the so-called genome-wide association study
(GWAS) approach,(2) very rapidly bringing the number of
identiﬁed BMD loci from none(3) to dozens(4) and currently
hundreds(5) in less than a decade of GWAS research. This has
resulted in an unprecedented leap in the number of factors and
pathways being linked to skeletal biology, some of which have
been shown to constitute in retrospect solid leads for
pharmacological treatment,(6,7) whereas others revealed clear
translational potential of a GWAS discovery.(8,9) The recipe of
such success in osteoporosis has been the result of combining
BMD (a highly heritable, quantitative, precise, and widely
available trait capable of capturing aspects of bone biology)
with an ever-growing increase in the sample size of the studies,
growing from tenths to now hundreds of thousands of
participants (allowing lowering the noise and increasing
precision in the process of causative genetic variant identiﬁca-
tion). Most ﬁndings arise from BMD GWAS, predominantly
because of the high heritability and widespread data availability
of BMD measurements. Efforts focusing on fracture outcomes
have been less proliﬁc despite similar sample sizes, which is
largely the consequence of lower heritability due to greater
environmental inﬂuence. Interestingly, to date all the genetic
determinants of fracture that have been identiﬁed by GWAS are
also associated with BMD. Because BMD does not completely
capture fracture risk (see above), this observation suggests that
approaches other than BMDmight yieldmore genetic factors for
fracture. So, does the ﬁeld indeed need to change the approach
and instead of focusing on BMD move toward targeting other
skeletal outcomes that can capture better the genetic factors
underlying fracture propensity?
In this issue of JBMR, Karasik and colleagues(10) have
performed a comprehensive determination of the heritability
and genetic correlation of bone strength properties in humans,
assessed from failure load values determined with micro-ﬁnite
element analysis (mFEA)measured by high-resolution peripheral
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quantitative computed tomography (HR-pQCT). This work was
carried out as part of the Framingham Heart Study(11) in one of
the largest samples with assessment of bone microarchitecture.
The FraminghamOsteoporosis Offspring Cohort, fromwhich the
participants are derived, constitutes a two-generational family-
based study where heritability can be assessed by determining
the variation in a trait, which is explained by the genetic
relatedness between individuals in the population.(12) Although
heritability estimates do not provide information about the
actual variants inﬂuencing the variation in a trait, they do
provide insight about the underlying genetic architecture of a
trait. Even better, when two or more traits are assessed in the
same population, the “shared heritability” or genetic correlation
can provide further understanding about common biologic
mechanisms between traits. This is crucial information for
launching genetic investigations into these skeletal traits but
also helps in the understanding of the properties of the
measurements and biological mechanisms underlying the
phenotype they measure, which in turn, can help understand
their relationship with fracture.
It has been established that areal BMD (though imperfect in its
ability to predict fracture) is a good proxy of bone strength,
accounting for up to 80% of the variation in bone strength.(13) As
proposed, the remaining unaccounted fraction of bone strength
is determined by “bone quality,” a composite term referring to
structural and material properties, deﬁned as comprising bone
mineralization, architecture, turnover, and micro-damage
accumulation.(14)
Peripheral quantitative computerized tomography (pQCT) in
its high-resolution (HR) and standard versions is a technology
able to assess properties that are not generated from areal
BMD measurements. With pQCT, volumetric BMD is measured
(vBMD), reﬂecting the actual 3D conﬁguration of bone, and
cortical and trabecular bone compartments can be separately
assessed. Previous work of the authors in the same study
population using HR-pQCT determined that vBMD and bone
microarchitecture indices measured at the distal radius
(unloaded) and tibia (loaded) bones were heritable and
signiﬁcantly genetically correlated to aBMD.(15) Those ﬁndings
imply that aBMD remains the trait of choice for the discovery
phase of genetic studies of osteoporosis, considering its higher
heritability, widespread availability of the measurement (war-
ranting large sample sizes crucial for GWAS), conﬁrmed
successful yield of discoveries, and (last but not least) its ability
to capture many aspects of bone composition.
In their current work, the authors have now focused on an
index of compressive bone strength derived from the HR-pQCT
measurements at the ultradistal radius and tibia, which is
represented as failure load obtained from micro-ﬁnite element
analysis. The heritability estimates (h2 of 42% to 54%) that were
obtained for the HR-pQCT-derived failure loads were similar to
those of aBMD measured at the same (forearm) or proxy
(femoral neck) skeletal sites, thereby indicating that these
HR-pQCT traits, like aBMD, may also constitute promising traits
for future genetic investigations. Using actual bone strength
indices as the outcomes of genetic studies will (at least in theory)
provide better understanding of the associations between
identiﬁed genetic variants and skeletal outcomes. Yet, the failure
loads at both skeletal sites were highly correlated with several of
the HR-pQCT bonemicroarchitecture indices andwith the aBMD
measurements. As expected, the shared heritability (genetic
correlation) was also high, reaching 95% between failure load at
the radius and forearmBMD and 70%between failure load at the
tibia and femoral neck BMD. This means that the variation in
genes associated with aBMD are likely to reﬂect genetic
pathways that affect bone strength. Although expected, this
observation offers validation of the importance of those
identiﬁed BMD-associated loci to skeletal pathways and
postulates that their effect on fracture, the clinical deleterious
consequence of low BMD, is likely because these variants exert
an effect on bone strength.
From another perspective, the authors are optimistic that the
study of failure load indices has the potential to identify genetic
risk factors of fracture, which are independent of aBMD. They
base their hopes on the fact that despite not observing
signiﬁcant differences, a trend of change was observed on the
heritability estimates after correction for aBMD. Typically, when
studying the genetics of complex diseases (including heritability
studies), sample size limitations do not allow conclusions to be
drawn from only one report. The conﬁdence intervals of the
estimates are wide, making it difﬁcult to determine the actual
effect of covariate adjustment on the heritability estimates. Then
again, heritability studies are liable to misconceptions, many of
which also affect the way we interpret their estimates. A given
heritability estimate of 50% means that in the sampled
population on average 50% of the total variance in failure
load can be explained by genetic differences between
individuals in a given environment. Therefore, the ethnic
background and sex and age composition of participants of
the Framingham Osteoporosis Study included in the analysis
need to be considered in the perspective of the reported
heritability estimates, together with the relevant environmental
inﬂuences in that population that might differ from those in
similar cohort studies conducted elsewhere.
The authors correct their estimates for sex and age to allow
generalization, acknowledging their limitation of not being able
to stratify and obtain estimates for those speciﬁc groups given
the resulting power issues. Heritability estimates of complex
traits like failure load are not expected to differ signiﬁcantly
between sexes; in contrast, the differences in age and
environmental exposures are very relevant and require further
study. The mean age of the study population was 72 years,
comprising lifelong environmental exposures that are expected
to result in underestimation of the lifelong heritability of a trait
and indirectly affect the ability to discriminate genetic effects
speciﬁc to failure load bone strength. Other factors inﬂuencing
the heritability estimates are related to secular trends being
different between populations (ie, physical activity, nutrition,
and other environmental factors). Correcting for these factors is
not trivial and actually not recommended in heritability studies,
as they may result in irreproducible estimates that cannot be
easily extrapolated between populations. The sex and age
correction applied by the authors sufﬁces for these under-
takings, while they also include additional models corrected for
body height to establish independence from skeletal size
components. They propose that the estimated failure load
heritability seems to be independent of bone size as inclusion of
height in the models increased the estimates slightly. In fact,
inclusion of additional covariates in the models can have the
effect of increasing heritability estimates by reducing the overall
phenotypic variance of the trait (while also potentially adjusting
out variance components arising from genetic shared factors).
This reduction of overall phenotypic variance (and resulting
slight increase in the heritability estimate) is likely achieved by
correction of measurement error captured by the body height
adjustment. A note of caution is also needed here for future
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genetic studies, as inclusion of heritable covariates in themodels
can actually result in unintended bias introducedwith respect to
the primary outcome as a result of the adjustment, ensuing
“collider” bias that might lead to false positives (spurious
associations).(16,17)
Typically, heritability studies of BMD have shown that
measurements of the axial skeleton tend to have higher
heritability estimates than those of the appendicular skeletal
sites. This is expected to occur in response to differential
exposure to environmental factors and also observed among
the appendicular sites between the “loaded” and “unloaded”
bones.(18,19) Interestingly, in contrast to BMD, the heritability
estimates of failure load did not differ signiﬁcantly between the
two sites despite the differences in skeletal loading. This can be
interpreted as failure load being a property of bone that is
reﬂecting more the genetic predisposition of bone strength
than the environmental inﬂuences affecting the skeleton. If this
is indeed the case, genetic studies of failure load could also
result in a high yield of discoveries when used in GWAS. On the
other hand, a very different genetic architecture from that of
BMD (comprising less frequent and common genetic variants
within genes affecting monogenic and complex forms of the
traits)(7) is not expected. Therefore, before the indices of
compressive bone strength used in this study can be readily
incorporated as outcomes of GWAS, the sample size of studies
with HR-pQCT measurements needs to increase several-fold to
reach the tens to hundreds of thousands of participants
achieved by current successful BMD GWAS.
From this perspective, we can expect that applying the GWAS
approach in an ever-expanding number of individuals with the
skeletal trait of interest (likely BMD) will continue to allow the
identiﬁcation of hundreds to thousands of genetic variants
underlying the risk of osteoporosis and fracture. This approach
needs to be complemented by studies performing functional
follow-up of the identiﬁed loci and their pathways but also by
enriching the set of investigated phenotypes that together can
help elucidate the processes underlying fracture susceptibility.
Unique opportunities arise in other settings, where the aBMD
measurement falls short in advancing the ﬁeld of genetics of
osteoporosis. Thus, the expected gains in knowledge from
association studies using aBMD (a single value measurement
resulting from a composite of mineral, mass, and size properties
of bone) are likely to be limited to detecting the involvement of a
gene or genomic region (locus) in bone biology; whereas,
combining the knowledge derived from association studies on
aBMD with those of the failure load indices (and even the other
bone microarchitecture indices measured by HR-pQCT) will
increase the understanding of how genetic variation inﬂuences
speciﬁc bone structure and compartments. This will hopefully
open translational opportunities in the context of fracture risk
etiology. On the other hand, when studying the genetic
predisposition of conditions where BMD does not characterize
well the actual risk of individuals (eg, fracture risk in diabetes,
atypical fractures), studying failure load bone strength can
provide valuable insight about the involvement of genes and
pathways in the pathogenesis of fracture in those conditions.
Current GWAS discoveries based on BMD are starting to
advance the ﬁeld of genetics of osteoporosis by means of
pinpointing drug targets that will potentially lead to the
development of improved therapies and preventive measures.
A single study of bone strength outcomes is unlikely to yield
new discoveries not related to BMD but will deﬁnitively provide
the basis for extending the understanding of several of
these genetic associations with BMD (bone size and density).
As previously postulated in this journal, studying and under-
standing bone strength is not enough.(20) Fracture is not always
a result of insufﬁcient strength. Therefore, studies limited to
BMD and bone strength will often miss other bone properties
that are inﬂuenced by genetic factors. This means that studying
material failure properties (ie, fracture toughness and fatigue
strength) and their associated (molecular)mechanistic pathways
is needed. As recently pointed out by Hernandez and van der
Meulen,(20) one of the factors limiting the advance of the ﬁeld is
the contention (misconception) that (as described above) the
skeletal properties underlying fracture susceptibility can be
separated into clearly deﬁned components that act indepen-
dently from each other. This is one of the reasons limiting the
success of genetic approximations, where the mechanistic
pathway leading to fracture can be conceived as a “melting
funnel pot” of multiple processes that ultimately inﬂuence
fracture risk, all of which have different degrees of genetic
contribution. With fracture risk constituting such a heteroge-
neous outcome, large samples need to be brought together to
identify the real yet weak effects of genetic variants inﬂuencing
complex traits. Either way, the assessment of those properties
not captured by studying bone strength alone needs to be
targeted by implementing new technologies and making them
widely available, neither of which is easy to achieve in the near
future. However, new promising technologies are showing
some promise in that direction (ie, MRI identiﬁcation of bone
marrow lesions and bone material strength measured by micro-
indentation). The study of Karasik and colleagues, in determin-
ing the heritability and genetic correlation between these novel
traits, BMD, and fracture risk, provides a solid start to assess
their potential as outcomes for genetic investigations and to
understand their interdependencies. Ultimately, the hope is
that this approach will be successful in bringing the ﬁeld
further toward fulﬁlling the expectations of translating genetic
discoveries into practical clinical applications.
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